| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
| 药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Following intragastric injection of 0.1–0.2 g/kg skatole in cattle or intravenous infusion of 0.06 g/kg skatole, the mean plasma concentration of skatole reached its maximum at 3 hours and 9 hours, respectively. In goats, intravenous infusion of 3-methylindole (3MI) containing (14)C-3MI over 2 hours, with propylene glycol as the solvent, rapidly cleared 3MI from plasma and tissues after infusion, with 81% of the radioactive material excreted in urine within 24 hours. The maximum concentration of unmetabolized 3MI in tissues ranged from 2.6 to 15 μg 3MI/g, with a concentration of 7.5 μg 3MI/g in lung tissue. The proportion of metabolites was highest in lung tissue. The data indicate that 3-methylindole (3MI) does not selectively accumulate in the lungs, and its concentration is lower than that typically associated with direct membrane damage. Metabolism/Metabolites Skatol is produced by bacteria in the gastrointestinal tract (small intestine and rumen) that degrade dietary tryptophan residues… Adult beef cattle grazing in dry pastures during the summer were transferred to lush pastures to induce acute bovine pulmonary edema and emphysema (ABPE), and to determine whether the concentration of 3-methylindole (3MI) in plasma and rumen fluid was related to… the development of ABPE. In vitro production of 3MI was observed in a culture medium inoculated with rumen fluid, indicating the presence of 3MI-producing microorganisms in the rumen. Clearly, bovine rumen microorganisms convert tryptophan (present in lush pastures) into 3MI, and the absorption of 3MI by animals may lead to the development of ABPE. Produced by indole-3-acetic acid. Produced in rats and wheat; FRYDMAN RB et al.; FEBS LETTERS 17: 273 (1971). Production of 5-hydroxypyrethrin and 7-hydroxypyrethrin in rats; DALGLIESH CE et al.; BIOCHEM J 70: 13P (1958). Production of 6-hydroxypyrethrin in rabbits; JEPSON JB et al.; BIOCHIM BIOPHYS ACTA 62: 91 (1962). Production of salicylic acid in Pseudomonas; PROCTOR MM; NATURE (LONDON) 181: 1345 (1958). /Excerpt from Table/ Goat jugular vein infusion (14) C-3-methylindole (3MI). The major metabolic pathways of 3-methylindole involve its production, suggesting that a mixed-function oxidase (pyrrole oxygenase) may be the major metabolic system. The minor metabolic pathways involve the oxidation of the methyl carbon of 3-methylindole. For more metabolic/metabolite (complete) data on 3-methylindole (6 metabolites in total), please visit the HSDB record page. The known metabolites of 3-methylindole include 3-methylindole-2,3-epoxide and 3-methyleneindoline. |
|---|---|
| 参考文献 | |
| 其他信息 |
Skatole is a methylindole with a methyl substituent at the 3-position. It is produced during the anaerobic metabolism of L-tryptophan in the digestive tract of mammals. It is a metabolite in both mammals and humans. 3-Methylindole has been reported in Tachigali glauca, Tecoma stans, and other organisms with relevant data. See also: ... See more ...
Mechanism of Action Nucleophilic thiols, such as glutathione, L-cysteine, and N-acetyl-L-cysteine, can protect microsomal proteins from the alkylation of the active metabolite of 3-methylindole. Bovine lung cytosol components can enhance the protective effect of these thiols. Pretreatment of sheep with diethyl maleate depletes glutathione, thereby exacerbating the pulmonary toxicity of 3-methylindole; while pretreatment with L-cysteine reduces the severity of this effect. These findings are consistent with the hypothesis that the electrophilic metabolite of 3-methylindole is responsible for its pulmonary toxicity and suggest that glutathione and glutathione S-transferases are involved in the detoxification process of this active metabolite. The results of incubation of various indole compounds with goat lung microsomes showed that only 3-methylindole could generate free radicals in an NADPH-dependent microsomal system, which was confirmed by spin trapping experiments. The enzymatic free radical generation of 3-methylindole suggests that the free radical mechanism of microsomal activation may be a specific mechanism for 3-methylindole-induced pulmonary toxicity. This study investigated the bioactivation of 3-methylindole (3MI) in human lung and liver tissues. 3MI is a highly selective pulmonary toxin for goats, and this study aimed to understand human susceptibility to 3MI toxicity. Human lung microsomes were prepared from eight organ transplant donors, and liver microsomes were selected from one of the donors. The turnover rate of 3MI in human lung microsomes was 0.23 ± 0.06 nmol/mg/min, lower than that in human liver microsomes (7.40 nmol/mg/min). These activities were NADPH-dependent and inhibited by the potent cytochrome P450 suicide substrate inhibitor, l-aminobenzotriazole. The covalent binding of 3MI reaction intermediates to human tissues was determined by incubating (14)C-3MI and NADPH with human lung and liver microsomal proteins. While human lung microsomes showed measurable covalent binding activity (2.74 ± 2.57 pmol/mg/min), the intensity of the reaction was only 4% of that in human liver microsomes and was also inhibited by l-aminobenzotriazole. Therefore, the bioactivation of 3MI to covalently bound intermediates is catalyzed by cytochrome P450 in human lung tissue. These activities were compared with those measured in goat tissue. Proteins from goat and human lung and liver microsomal incubation solutions were incubated with radiolabeled 3MI. The radiolabeled proteins were then analyzed by SDS-PAGE and HPLC, respectively, and developed by autoradiography and radiochromatography. The results showed that the 57 kDa protein was the most significant alkylation target associated with 3MI reaction intermediates. These data suggest that humans may be susceptible to 3MI-mediated toxicity, and the specificity of covalent binding and the degree of binding to target proteins may play an important role in the selective susceptibility of organs and species to 3MI pulmonary toxicity. Therapeutic Use Experimental Use: Drug (Veterinary): 5 mg skatole/day intramuscularly for 15 consecutive days in infected guinea pigs weighing 200-300 g showed anti-tuberculosis activity against Mycobacterium tuberculosis. |
| 分子式 |
C9H9N
|
|---|---|
| 分子量 |
131.17446
|
| 精确质量 |
131.073
|
| CAS号 |
83-34-1
|
| 相关CAS号 |
Skatole-d3;111399-60-1;Skatole-d8;697807-03-7
|
| PubChem CID |
6736
|
| 外观&性状 |
Off-white to gray solid powder
|
| 密度 |
1.1±0.1 g/cm3
|
| 沸点 |
265.1±9.0 °C at 760 mmHg
|
| 熔点 |
92-97 °C(lit.)
|
| 闪点 |
112.5±11.3 °C
|
| 蒸汽压 |
0.0±0.5 mmHg at 25°C
|
| 折射率 |
1.655
|
| LogP |
2.6
|
| tPSA |
15.79
|
| 氢键供体(HBD)数目 |
1
|
| 氢键受体(HBA)数目 |
0
|
| 可旋转键数目(RBC) |
0
|
| 重原子数目 |
10
|
| 分子复杂度/Complexity |
122
|
| 定义原子立体中心数目 |
0
|
| InChi Key |
ZFRKQXVRDFCRJG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H9N/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6,10H,1H3
|
| 化学名 |
3-methyl-1H-indole
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ~100 mg/mL (~762.37 mM)
|
|---|---|
| 溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (19.06 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (19.06 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (19.06 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.6237 mL | 38.1185 mL | 76.2369 mL | |
| 5 mM | 1.5247 mL | 7.6237 mL | 15.2474 mL | |
| 10 mM | 0.7624 mL | 3.8118 mL | 7.6237 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。